Claimable CAIHL draft report

Claimable: CAIHL reassessment

September 8, 2026. Published AI-assisted draft.

Claimable’s patient appeal workflow, including sponsored referrals, documents patient editing and approval before delivery. Enterprise analytics have a separate scope. Sponsorship and contradictory sharing language require scrutiny, with implementation unverified.

Scope and agency posture

Claimable’s patient appeal workflow, including sponsored referrals, documents patient editing and approval before delivery. Enterprise analytics have a separate scope. Sponsorship and contradictory sharing language require scrutiny, with implementation unverified.

Posture: Potentially agency-expanding, with sponsorship-alignment caveat.

Axis: 72/100, retained provisionally. No numerical recalibration was performed.

Sources and documented findings

• The provider page says patients can change the letter, optionally share it with their clinician, and approve it before delivery. Provider workflow, steps 3–4, freshly retrieved September 8. Vendor description, not observed behavior. General export and reuse rights were not established.

• The pharma page describes patient approval, sponsorship disclosure at consent, and access revocation. Pharma FAQ, recovered September 8 evidence. Actual consent prominence and sponsor influence on available strategies remain untested.

• Partner appeal credits are spent on patient submission and returned after 30 days without action. Partner service agreement. This agreement does not describe every enterprise deployment.

• Privacy wording both denies promotional sharing and permits consent-based partner analysis or marketing. Privacy policy, sharing section. The passages do not establish an actual unauthorized disclosure.

Patient authority

Inference from the documented workflow: the documented approval gate supports patient direction within the appeal task. Provider referral and sponsorship do not erase that gate. Authority over a different treatment goal or enterprise strategy is not established.

Critical capacity

Editorial assessment: drafting and delivery can make contesting a denial practically possible. Evidence-backed argument is a documented product claim, not verified citation quality or proof of broader critical understanding.

Informed control

Editorial assessment: the public controls are meaningful, but contradictory sharing language and unobserved consent limit confidence in how patients evaluate the service's conditions. Commercial interests may coincide with a chosen appeal without encompassing all patient interests.

Assessment and limits

Claimable’s patient appeal workflow, including sponsored referrals, documents patient editing and approval before delivery. Enterprise analytics have a separate scope. Sponsorship and contradictory sharing language require scrutiny, with implementation unverified.

Confidence: Medium for published documentation, low for implementation.

Remaining uncertainty: Consent presentation, independent output-use rights, control outside the supported appeal goal, and actual partner data flows.

Published documentation is evidence of stated conditions, not proof of actual implementation. Unknowns did not receive automatic negative points. Funding, sponsorship, and public code do not determine agency by themselves.

Review provenance

• Reviewer/model: OpenAI Codex / GPT-6.
• Method: Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.
• Human review: Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.
• Earlier review: 2026-06-10. Historical assessment. Earlier claims are not automatically reverified by this publication.